Pfizer Doses First Patient In Phase 2/3 Trial For Daily COVID Pill

Share it with your friends Like

Thanks! Share it with your friends!

Close

By Michael By Tyler Durden Pfizer revealed on Wednesday that it had finally dosed its first patient participating in the Phase 2/3 study examining the efficacy of PF-07321332, an orally administered protease… …read more

Source: Natural Blaze

    

  • Rating:
  • Views:98 views
  • Categories: Health